Read more about Jubilant Pharmova Q4 PAT declines 19% to Rs 173 cr on Business Standard. On a consolidated basis, Jubilant Pharmova s net profit (from continuing operations) dropped 18.64% to Rs 172.68 crore on 0.71% rise in total revenue from operations to Rs 1,579.78 crore in Q4 March 2021 over Q4 March 2020.
Read more about India Ratings assigns Jubilant Ingrevia IND AA rating on Business Standard. Credit ratings agency India Ratings and Research (Ind-Ra) assigned Jubilant Ingrevia (JVL) a long-term issuer rating of IND AA with a stable outlook.
Read more about Jubilant Pharmova subsidiary to invest $92 mln for expansion on Business Standard. Jubilant Pharma, a wholly-owned subsidiary of Jubilant Pharmova, announced $92 million investment plans to expand sterile injectable manufacturing capacity at its Spokane site in Washington, US.